The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Zarontin 250 mg/5 ml Syrup

Lexon Pharmaceuticals (Ireland) LimitedPPA23176/042/001

Main Information

Trade NameZarontin 250 mg/5 ml Syrup
Active SubstancesEthosuximide
Dosage FormSyrup
Licence HolderLexon Pharmaceuticals (Ireland) Limited
Licence NumberPPA23176/042/001

Group Information

ATC CodeN03AD01 ethosuximide


License statusAuthorised
Licence Issued24/06/2022
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back